Cited by 660Monoclonal and Polyclonal Antibodies ResearchProtein Degradation and InhibitorsToxin Mechanisms and Immunotoxins

The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.

Exploring the next generation of antibody–drug conjugates

Tsuchikama, Kyoji, Anami, Yasuaki, Ha, Summer Y. Y., Yamazaki, Chisato M.·2024·Nature Reviews Clinical Oncology

DOI 10.1038/s41571-023-00850-2

Open this paper in CoChat — free account

Abstract

Antibody-drug conjugates (ADCs) are a promising cancer treatment modality that enables the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full potential of this platform necessitates innovative molecular designs to tackle several clinical challenges such as drug resistance, tumour heterogeneity and treatment-related adverse effects. Several emerging ADC formats exist, including bispecific ADCs, conditionally active ADCs (also known as probody-drug conjugates), immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs, and each offers unique capabilities for tackling these various challenges. For example, probody-drug conjugates can enhance tumour specificity, whereas bispecific ADCs and dual-drug ADCs can address resistance and heterogeneity with enhanced activity. The incorporation of immune-stimulating and protein-degrader ADCs, which have distinct mechanisms of action, into existing treatment strategies could enable multimodal cancer treatment. Despite the promising outlook, the importance of patient stratification and biomarker identification cannot be overstated for these emerging ADCs, as these factors are crucial to identify patients who are most likely to derive benefit. As we continue to deepen our understanding of tumour biology and refine ADC design, we will edge closer to developing truly effective and safe ADCs for patients with treatment-refractory cancers. In this Review, we highlight advances in each ADC component (the monoclonal antibody, payload, linker and conjugation chemistry) and provide more-detailed discussions on selected examples of emerging novel ADCs of each format, enabled by engineering of one or more of these components.

Integrity signals

Registry

Crossref · 10.1038/s41571-023-00850-2

Cites

248 of 248 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,681
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209

Show all 248 references

Research works printed but not linked: 1

CytomX Therapeutics Inc. CytomX therapeutics presents overview of conditionally-activated antibody-drug conjugate (ADC) programs including next generation EpCAM-targeting CX-2051. CytomX Press Release Details https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-presents-overview-conditionally-activated/ (2022).

Sorted by citations

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Zhao, X., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 331
Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 320
Cancer therapy with antibodies
Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., & Zhou, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00690-x · Cited by 292
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 263
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 114
Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions
Chen, B., Zheng, X., Wu, J., Chen, G., Yu, J. Q., Xu, Y. X., Wu, W. K. K., Tse, G. M.-K., To, K. F., & Kang, W. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02489-2 · Cited by 121
Synthetic Biology in Natural Product Biosynthesis
Seshadri, K., Abad, A. N. D., Nagasawa, K. K., Yost, K. M., Johnson, C. W., Dror, M. J., & Tang, Y. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00567 · Cited by 94
Resistance to antibody–drug conjugates: A review
Li, S., Zhao, X., Fu, K., Zhu, S., Pan, C., Yang, C., Wang, F., To, K. K. W., & Fu, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.12.036 · Cited by 100
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 105
Trop2-targeted therapies in solid tumors: advances and future directions
Liu, X., Ma, L., Li, J., Sun, L., Yang, Y., Liu, T., Xing, D., Yan, S., & Zhang, M. (2024) · Theranostics · doi:10.7150/thno.98178 · Cited by 89
The next generation of immunotherapies for lung cancers
Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 96
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, P. Y., Weller, M., Lee, E. Q., Touat, M., Khasraw, M., Rahman, R. M., Platten, M., Lim, M. K., Winkler, F., Horbinski, C., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf177 · Cited by 113
From cell-SELEX to tissue-SELEX for targeted drug delivery and aptamer nanomedicine
Wong, K., Wong, M., Lee, J. H., & Liu, J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115646 · Cited by 82
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P., & Thurber, G. M. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00869-w · Cited by 87
Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
Lei, Y., Zheng, M., Chen, P., Chen, P., Loh, T., & Liu, H. (2025) · ChemMedChem · doi:10.1002/cmdc.202500262 · Cited by 69
Receptor-ligand interactions for optimized endocytosis in targeted therapies
Sung, Y., Choi, Y., Kim, E. S., Ryu, J. H., & Kwon, I. C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.060 · Cited by 64
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
Zhao, S., Cheng, Y., Wang, Q. J., Li, X., Liao, J., Rodon, J. A., Meng, X., Luo, Y., Chen, Z., Wang, W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03638-2 · Cited by 67
A pivotal decade for bispecific antibodies?
Surowka, M., & Klein, C. (2024) · mAbs · doi:10.1080/19420862.2024.2321635 · Cited by 64
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
He, J., Zeng, X., Wang, C., Wang, E., & Li, Y. (2024) · MedComm · doi:10.1002/mco2.671 · Cited by 60
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Parit, S., Manchare, A., Gholap, A. D., Mundhe, P., Hatvate, N. T., Rojekar, S. V., & Patravale, V. B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124211 · Cited by 59
Antibody–drug conjugates: prospects for the next generation
Grairi, M., & Borgne, M. L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104241 · Cited by 61
The molecular blueprint of targeted radionuclide therapy
Primac, I., Tabury, K., Tasdogan, A., Baatout, S., & Herrmann, K. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01069-z · Cited by 63
Trop2-targeted therapy in breast cancer
Hu, Y., Zhu, Y., Qi, D., Tang, C., & Zhang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00633-6 · Cited by 54
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Antibody-drug conjugates in cancer therapy: applications and future advances
Long, R., Zuo, H., Tang, G., Zhang, C., Yue, X., Yang, J., Luo, X., Deng, Y., Qiu, J.-Y., Li, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1516419 · Cited by 56
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses
Dong, Y., Zhang, Z., Luan, S., Zheng, M., Wang, Z., Chen, Y., Chen, X., Tong, A., & Yang, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009710 · Cited by 49
Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads
Xi, M., Zhu, J., Zhang, F., Shen, H., Chen, J., Xiao, Z., Huangfu, Y., Wu, C., Sun, H., & Xia, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116709 · Cited by 47
Dual-payload antibody–drug conjugates: Taking a dual shot
Tao, J., Gu, Y., Zhou, W., & Wang, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116995 · Cited by 47
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies
Zhou, K., Liu, X., & Zhu, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01752-9 · Cited by 52
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 59
Engineered multi-domain lipid nanoparticles for targeted delivery
Liu, Z., Chen, J., Xu, M., Ho, S., Wei, Y., Ho, H., & Yong, K. (2025) · Chemical Society Reviews · doi:10.1039/d4cs00891j · Cited by 63
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations
Wen, M., Yu, A., Park, Y. J., Calarese, D. A., Gerber, H. P., & Yin, G. (2025) · mAbs · doi:10.1080/19420862.2025.2498162 · Cited by 42
Targeted protein degradation in the transmembrane and extracellular space
Zhu, R., Zhang, H., & Chen, P. R. (2025) · Science · doi:10.1126/science.adx5094 · Cited by 43
HER2-low gastric cancer: is the subgroup targetable?
Shimozaki, K., Fukuoka, S., Ooki, A., & Yamaguchi, K. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103679 · Cited by 43
Applications of cell penetrating peptide-based drug delivery system in immunotherapy
Du, J., Zhang, R., Jiang, S., Xiao, S., Liu, Y., Niu, Y., Zhao, W.-X., Wang, D., & Ma, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1540192 · Cited by 42
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Pérez, V. M. M., Baselga, M., & Schuhmacher, A. J. (2024) · Cancers · doi:10.3390/cancers16152681 · Cited by 43
Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
Mao, K., Chen, P., Sun, H., Zhong, S., Zheng, H., & Xu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1425617 · Cited by 38
Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome
Leung, K., Schaefer, K., Lin, Z., Yao, Z. W., & Wells, J. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00554 · Cited by 44
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
Zhang, J., Liu, R., Wang, S., Feng, Z. C., Yang, H., Gao, S., Li, X., Yao, X., Chen, J., Gong, Z., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.04.009 · Cited by 37
Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology
Lu, Y., Huang, W., Li, Y., Xu, Y., Wei, Q., Sha, C., & Guo, P. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01159-2 · Cited by 44
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
Tong, Y., Fan, X., Liu, H., & Liang, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1495675 · Cited by 36
Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives
Valle, I., Grinda, T., Antonuzzo, L., & Pistilli, B. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00829-5 · Cited by 43
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis
Tang, S., Wynn, C., Le, T., McCandless, M. G., Zhang, Y., Patel, R., Maihle, N. J., & Hillegass, W. B. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10231-5 · Cited by 40
Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management
Dernbach, G., Eich, M., Dragomir, M. P., Anders, P., Jurczok, N., Stief, C. G., Jurmeister, P. S., Schlomm, T., Klauschen, F., Horst, D. A., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100753 · Cited by 35
Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach
Ma, Z., Zhou, M., Chen, H., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02975 · Cited by 43
Antibody-drug conjugates in breast cancer: current evidence and future directions
Li, N., Yang, L., Zhao, Z., Du, T., Li, N., Tang, J., & Tang, J. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00632-9 · Cited by 38
Cracking the Codes behind Cancer Cells’ Immune Evasion
Mundhara, N., & Sadhukhan, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168899 · Cited by 37
Precision-engineered PROTACs minimize off-tissue effects in cancer therapy
Shi, J., Wang, L., Zeng, X., Xie, C., Meng, Z., Campbell, A., Wang, L., Fan, H., & Sun, H. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1505255 · Cited by 35
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
Li, S., Guo, Y., Che, J., Dai, H., & Dong, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01982 · Cited by 35
Understanding the Toxicity Profile of Approved ADCs
Martinez, P. B., de Sá, A. L., Díaz‐Tejeiro, C., Paniagua‐Herranz, L., Sanvicente, A., López-Cade, I., Pérez‐Segura, P., Alonso‐Moreno, C., Nieto‐Jiménez, C., & Ocaña, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020258 · Cited by 34
Evolving roles of MET as a therapeutic target in NSCLC and beyond
Lee, J. B., Shim, J. S. G., & Cho, B. C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01051-9 · Cited by 34
Emerging paradigms and recent progress in targeting ErbB in cancers
Stoup, N., Liberelle, M., Lebègue, N., & SEUNINGEN, I. V. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.009 · Cited by 33
RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond
Ding, Y.-P., Liu, C., & Yu, K. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00648-1 · Cited by 34
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
Poudel, Y. B., Thakore, R. R., & Chekler, E. P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01289 · Cited by 29
Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding
Li, J., Yu, J., Song, J. T., Zhang, Y., Li, N., Wang, Z., Qin, M., Zhao, M., Zhang, B., Huang, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63198-4 · Cited by 33
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Tardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 30
Fluorogenic Platform for Real-Time Imaging of Subcellular Payload Release in Antibody–Drug Conjugates
Nadal‐Bufí, F., Salomon, P. L., Moliner, F. D., Sarris, K., Wang, Z., Wills, R. D., Marin, V. L., Shi, X., Zhou, K., Wang, Z., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c16842 · Cited by 28
Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors
Lv, Y., Cui, X., Li, T., Liu, C., Wang, A., Wang, T., Zhou, X., Li, R., Zhang, F., Hu, Y., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01655-6 · Cited by 29
Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
Lin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 28
Protein-based nanomedicines for cancer theranostics: From supramolecular self-assembly to AI-driven design and applications
Cheng, H., Yang, C., Wang, J., Liu, H., Zhang, K., Wu, R., Li, J., Fang, Y., Hu, R., Jeong, H., et al. (2025) · Chem · doi:10.1016/j.chempr.2025.102624 · Cited by 29
Chemical diversity of reagents that modify RNA 2′-OH in water: a review
Shioi, R., & Kool, E. T. (2024) · Chemical Science · doi:10.1039/d4sc05317f · Cited by 25
Programmable Circular Multispecific Aptamer-Drug Engager to Broadly Boost Antitumor Immunity
Chen, J., Chi, H., Wang, C., Du, Y., Wang, Y., Yang, S., Jiang, S., Lv, X., He, J., Chen, J., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06189 · Cited by 25
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors
Cheng, Y., Lü, J., Zhang, C., Yan, W., Zhu, P., Qin, Q., & Gong, L. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf004 · Cited by 25
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
Shi, X., Tang, K., Zhang, Q., Han, Q., Quan, L., Li, Y., Cui, J., Feng, N., Gong, J., Shang, B., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1556245 · Cited by 24
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 25
Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives
Wu, S., & Thawani, R. (2025) · Cancers · doi:10.3390/cancers17050801 · Cited by 26
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma
Leung, Y., Llauradó, M., Cameron, A., Da-Anoy, A., Cook, L. S., Hoenisch, J., Ghesquiere, C., Gaillard, S. L., Schmid, J., Dawson, A., et al. (2025) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e74 · Cited by 24
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy
Xu, X., Yu, T., & Wang, Z. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103012 · Cited by 23
Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
Zhou, X., Han, Y., Fang, Y., Ma, P., Zhou, J., Jiang, Y., Xing, S., Tang, Q., Hou, Y., Wang, S., et al. (2025) · Med · doi:10.1016/j.medj.2025.100849 · Cited by 26
A New Age of Drug Delivery: A Comparative Perspective of Ferritin–Drug Conjugates (FDCs) and Antibody–Drug Conjugates (ADCs)
Hong, J., Li, K., He, J., & Liang, M. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00254 · Cited by 23
Therapeutic potential of cis-targeting bispecific antibodies
Oslund, R., Holland, P. M., Lesley, S. A., & Fadeyi, O. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.07.004 · Cited by 23
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
Aliaga, P. T., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Signore, E. D., Passaro, A., & de Marinis, F. (2025) · Molecules · doi:10.3390/molecules30122645 · Cited by 22
Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers
Armstrong, G. B., Graham, H., Cheung, A., Montaseri, H., Burley, G. A., Karagiannis, S. N., & Rattray, Z. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115648 · Cited by 23
How multispecific molecules are transforming pharmacotherapy
Deshaies, R. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01262-w · Cited by 25
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
Shapiro, M. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379738 · Cited by 22
Antibody–drug conjugates and immune checkpoint inhibitors in cancer treatment: a systematic review and meta-analysis
Zhang, L., Yan, Y., Gao, Y., Chen, Y., Yu, J., Ren, N., & Sun, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-68311-z · Cited by 27
Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses
Zhang, B., Zhang, Z., Gao, J., Lu, S., Pang, R., Li, D., Huang, X., Qin, N., Liu, L., & Wang, Z. (2024) · iScience · doi:10.1016/j.isci.2024.111536 · Cited by 24
Programmable protein ligation on cell surfaces
Kofoed, C., Erkalo, G., Tay, N. E. S., Ye, X., Lin, Y., & Muir, T. W. (2025) · Nature · doi:10.1038/s41586-025-09287-2 · Cited by 27
Recent Advances in Peptide Linkers of Antibody–Drug Conjugates
Yang, L., Ma, J., Liu, B., Li, Y., Ma, Y., Chen, H., & Han, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01500 · Cited by 21
From discovery to the clinic: structural insights, engineering options, clinical, and ‘next wave’ applications of camelid-derived single-domain antibodies
Evers, A., Guarnera, E., Pekar, L., & Zielonka, S. (2025) · mAbs · doi:10.1080/19420862.2025.2583210 · Cited by 23
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Tonon, G., Rizzolio, F., Visentin, F., & Scattolin, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168651 · Cited by 21
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
Vasiyani, H., & Wadhwa, B. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111647 · Cited by 20
New targets and new drugs for hepatobiliary cancers
Chan, S. L., Lamarca, Á., Hsu, C., Moreno, V., Chan, L. L., & Keenan, B. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.018 · Cited by 23
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics
Corrigan, D. T., Tanwar, A., Du, M., Martin, A. M., & Zang, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.008 · Cited by 22
Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy
Yuan, Y., Zhuoga, C., Zeng, C., Zhou, W., Chen, W., Xu, Z. C., & Jiang, X. (2025) · Polymer science & technology. · doi:10.1021/polymscitech.5c00080 · Cited by 20
Mechanisms of resistance to antibody-drug conjugates in breast cancer
Çerçi, B., Saatci, Ö., Basik, M., & Şahin, Ö. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101353 · Cited by 19
Antibody–Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer
Jacob, J., Anami, Y., High, P. C., Liang, Z., Subramanian, S., Ghosh, S. C., AghaAmiri, S., Guernsey-Biddle, C., Tran, H., Rowe, J. H., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0798 · Cited by 20
Self-citation
Chemical Process Development in the Pharmaceutical Industry in Europe—Insights and Perspectives from Industry Scientists
Krueger, J. I., Dieskau, A. P., Hassfeld, J., Gries, J., Block, O., Weinmann, H., Kaufmann, D., Hildbrand, S., Kraft, V., Moeckel, R., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202420719 · Cited by 18
A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation
Zhang, L. N., Zhou, M., Lu, C., Zhao, P., Shi, N., Zhou, Y., Yao, C., Yang, X., Tian, J., Wang, J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03868-z · Cited by 18
Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics
Kobzev, D., Kulyk, O., Barmin, R. A., Tatarets, A. L., Pallares, R. M., Kiessling, F. M., Lammers, T., & Peña, Q. (2026) · Chemical Society Reviews · doi:10.1039/d6cs00165c · Cited by 25
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
Raja, A., Kasana, A., & Verma, V. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01270-y · Cited by 19
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
Gao, Y., Xia, Y., Chen, Y., Zhou, S., Fang, Y., Yu, J., Zhang, L., & Sun, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1459368 · Cited by 17
177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Yamaguchi, A., Yamazaki, C. M., Anami, Y., Ha, S. Y. Y., Xiong, W., Ta, R. T., Zhang, N., Manning, H. C., An, Z., & Tsuchikama, K. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0254 · Cited by 17
Self-citation
Recent developments in bioconjugation: From strategies to design and clinical applications
Samieipour, F., Dianat‐Moghadam, H., & Khanahmad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118593 · Cited by 20

Authors: Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M.
Affiliations: Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
Corresponding author: Tsuchikama, Kyoji
ORCID: Tsuchikama, Kyoji
Anami, Yasuaki
Ha, Summer Y. Y.
Yamazaki, Chisato M.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2024-01-08
Volume: 21
Issue: 3
Pages: 203-223
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/s41571-023-00850-2
OpenAlex: W4390673654
Cited by: 659
References: 248
Citations by year: 2026: 282 · 2025: 270 · 2024: 106
FWCI: 42.66
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Defense (W81XWH1910598, W81XWH)
National Institutes of Health (W81XWH)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Keywords: antibody-drug conjugates, drug resistance, tumor heterogeneity, linker chemistry, chemical conjugation, payload design, patient stratification, biomarkers, treatment-refractory cancer, multimodal cancer therapy
MeSH terms: Antibodies, Monoclonal, Antineoplastic Agents, Pharmaceutical Preparations, Humans, Neoplasms, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exploring the next generation of antibody–drug conjugates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks